Munich, Germany, February 26th, 2014: SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases, today announced the first publication covering the key characteristics and therapeutic potential of its monoclonal anti-FcRIIB-antibody SM201.
SM201 is a proprietary monoclonal antibody acting synergistically with the Fc-gamma-receptor IIB (FcRIIB) on B-cells as well as on other human immune cells. FcRIIB is an extremely powerful regulator of the antibody-mediated immune response and plays a crucial role in suppressing autoimmunity by regulating B-cell responses as well as effector functions of other cells. The modulation of the inhibitory activity of FcRIIB constitutes a highly attractive approach for the development of innovative immunotherapeutic drugs. The article describes the anti-hFcRIIB antibody, SM201, which is highly specific and binds to an epitope of human FcRIIB in such a manner that it does not interfere with the natural binding of IgG to the same receptor. The authors demonstrate that the humanized monoclonal antibody with these unique features works synergistically with immune complexes and thereby may represent a superior option for the treatment of antibody-mediated autoimmune diseases, including a more favorable safety profile with better long-term safety, compared to other currently available therapeutics.
Dr. Peter Sondermann, CSO of SuppreMol GmbH stated: "We are very proud to have succeeded in developing an antibody against the human inhibitory FcIIB Receptor that has such unique features. I am convinced that SM201 will have the potential to play a key role in the management of autoimmune diseases and other immunological disorders in the future."
Dr. Klaus Schollmeier, CEO of SuppreMol GmbH added: "I am excited about the progress we have made with our preclinical antibody platform. The unique features of SM201 will enable us to develop a whole family of antibodies that modulate the FcIIB receptor signaling pathway. Since the time from bench to clinic is one of the key elements of success of a novel medication, we have already started talking to different companies about partnerships. We are thrilled about the high level of interest in our monoclonal antibody program and this novel therapeutic approach."
The article published in "Immunology Letters" is available online at: http://dx.doi.org/10.1016/j.imlet.2014.01.012
SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases. The company is pioneering the clinical relevance of Fc-gamma IIB receptor (FcRIIB), as a therapeutic target. The company's lead product SM101, a recombinant soluble human FcRIIB is currently in phase II clinical development for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE). SuppreMol's pipeline also includes a proprietary monoclonal antibody family that targets the human FcIIB receptor with high specificity without blocking immune complex-binding to the receptor. These unique features trigger and enhance the immunesuppressive function of the endogenous receptor synergistically either in the presence (SM201) or also in absence (SM211) of pathogenic immune complexes. The first two antibodies derived from this program, SM201 and SM211, have met proof of concept in vivo and are currently in preclinical development. SuppreMol was founded as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised € 51.4 million through private investors. Major shareholders in the company include MIG Fonds, BioMedPartners AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube.
Dr. Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680